Is MNOV or SRZN more profitable?

MediciNova has a net margin of -1,962.98% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat MediciNova's return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,962.98% -27.28% -25.24% Surrozen -4,810.50% N/A -154.08%

Do analysts recommend MNOV or SIGA?

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 508.27%. Given MediciNova's stronger consensus rating and higher possible upside, equities analysts clearly believe MediciNova is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

MediciNova (MNOV) Competitors

$1.37 +0.01 (+0.74%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$1.37 +0.00 (+0.07%)

As of 07/14/2026 06:39 PM Eastern

Compare

MNOV vs. FBRX, NAGE, SRZN, SIGA, and IKT

Should you buy MediciNova stock or one of its competitors? MarketBeat compares MediciNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediciNova include Forte Biosciences (FBRX), Niagen Bioscience (NAGE), Surrozen (SRZN), Siga Technologies (SIGA), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry.

How does MediciNova compare to Forte Biosciences?

MediciNova (NASDAQ:MNOV) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

MediciNova has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market.

In the previous week, Forte Biosciences had 13 more articles in the media than MediciNova. MarketBeat recorded 15 mentions for Forte Biosciences and 2 mentions for MediciNova. Forte Biosciences' average media sentiment score of 0.91 beat MediciNova's score of 0.44 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Neutral
Forte Biosciences	Positive

MediciNova presently has a consensus price target of $8.33, indicating a potential upside of 508.27%. Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 55.09%. Given MediciNova's stronger consensus rating and higher possible upside, equities analysts clearly believe MediciNova is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

9.9% of MediciNova shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 4.4% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MediciNova has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	164.47	-$12M	-$0.23	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

Forte Biosciences has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Forte Biosciences	N/A	-106.17%	-85.50%

Summary

MediciNova beats Forte Biosciences on 10 of the 15 factors compared between the two stocks.

How does MediciNova compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to MediciNova's net margin of -1,962.98%. Niagen Bioscience's return on equity of 22.68% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
MediciNova	-1,962.98%	-27.28%	-25.24%

In the previous week, Niagen Bioscience had 7 more articles in the media than MediciNova. MarketBeat recorded 9 mentions for Niagen Bioscience and 2 mentions for MediciNova. Niagen Bioscience's average media sentiment score of 0.66 beat MediciNova's score of 0.44 indicating that Niagen Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Niagen Bioscience	Positive
MediciNova	Neutral

Niagen Bioscience presently has a consensus price target of $10.50, indicating a potential upside of 219.15%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 508.27%. Given MediciNova's higher possible upside, analysts clearly believe MediciNova is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Niagen Bioscience has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.01	$17.38M	$0.21	15.67
MediciNova	$410K	164.47	-$12M	-$0.23	N/A

Summary

Niagen Bioscience beats MediciNova on 12 of the 16 factors compared between the two stocks.

How does MediciNova compare to Surrozen?

MediciNova (NASDAQ:MNOV) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

MediciNova presently has a consensus price target of $8.33, indicating a potential upside of 508.27%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 91.96%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Surrozen	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

MediciNova has a net margin of -1,962.98% compared to Surrozen's net margin of -4,810.50%. Surrozen's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Surrozen	-4,810.50%	N/A	-154.08%

MediciNova has higher earnings, but lower revenue than Surrozen. MediciNova is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	164.47	-$12M	-$0.23	N/A
Surrozen	$3.48M	73.00	-$242.03M	-$37.59	N/A

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, MediciNova and MediciNova both had 2 articles in the media. MediciNova's average media sentiment score of 0.44 equaled Surrozen'saverage media sentiment score.

Company	Overall Sentiment
MediciNova	Neutral
Surrozen	Neutral

Summary

MediciNova beats Surrozen on 8 of the 13 factors compared between the two stocks.

How does MediciNova compare to Siga Technologies?

MediciNova (NASDAQ:MNOV) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

In the previous week, MediciNova and MediciNova both had 2 articles in the media. Siga Technologies' average media sentiment score of 0.93 beat MediciNova's score of 0.44 indicating that Siga Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Neutral
Siga Technologies	Positive

9.9% of MediciNova shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 2.7% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	164.47	-$12M	-$0.23	N/A
Siga Technologies	$94.57M	2.59	$23.28M	$0.27	12.67

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 508.27%. Given MediciNova's stronger consensus rating and higher possible upside, equities analysts clearly believe MediciNova is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Siga Technologies has a net margin of 21.58% compared to MediciNova's net margin of -1,962.98%. Siga Technologies' return on equity of 10.60% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Siga Technologies	21.58%	10.60%	8.94%

MediciNova has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Siga Technologies beats MediciNova on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Inhibikase Therapeutics?

MediciNova (NASDAQ:MNOV) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Inhibikase Therapeutics had 6 more articles in the media than MediciNova. MarketBeat recorded 8 mentions for Inhibikase Therapeutics and 2 mentions for MediciNova. Inhibikase Therapeutics' average media sentiment score of 1.10 beat MediciNova's score of 0.44 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Neutral
Inhibikase Therapeutics	Positive

MediciNova has higher revenue and earnings than Inhibikase Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	164.47	-$12M	-$0.23	N/A
Inhibikase Therapeutics	$260K	1,046.08	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

MediciNova has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

MediciNova presently has a consensus price target of $8.33, indicating a potential upside of 508.27%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 162.14%. Given MediciNova's higher possible upside, equities analysts clearly believe MediciNova is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11

Summary

MediciNova and Inhibikase Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.94M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.96	20.98	27.01	24.38
Price / Sales	164.47	311.10	522.34	91.89
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	1.61	8.54	10.80	6.33
Net Income	-$12M	$23.83M	$3.59B	$331.02M
7 Day Performance	-2.14%	-2.77%	-1.49%	-0.33%
1 Month Performance	9.60%	5.85%	2.79%	-1.29%
1 Year Performance	11.38%	52.15%	28.56%	21.30%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	2.0642 of 5 stars	$1.37 +0.7%	$8.33 +508.3%	+7.0%	$66.94M	$410K	N/A	10	Short Interest Increase
FBRX Forte Biosciences	2.2302 of 5 stars	$22.25 +9.0%	$67.00 +201.1%	+339.0%	$283.41M	N/A	N/A	5	Analyst Upgrade
NAGE Niagen Bioscience	4.3854 of 5 stars	$3.45 -1.4%	$10.50 +204.3%	-70.8%	$278.76M	$129.42M	16.43	120
SRZN Surrozen	2.8835 of 5 stars	$23.01 -2.7%	$42.00 +82.5%	+154.1%	$274.70M	$3.48M	N/A	80	Short Interest Increase
SIGA Siga Technologies	0.7295 of 5 stars	$3.67 -2.1%	N/A	-50.1%	$268.96M	$94.57M	13.59	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. FBRX, NAGE, SRZN, SIGA, and IKT

How does MediciNova compare to Forte Biosciences?

Summary

How does MediciNova compare to Niagen Bioscience?

Summary

How does MediciNova compare to Surrozen?

Summary

How does MediciNova compare to Siga Technologies?

Summary

How does MediciNova compare to Inhibikase Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. FBRX, NAGE, SRZN, SIGA, and IKT

How does MediciNova compare to Forte Biosciences?

Which has more risk & volatility, MNOV or FBRX?

Does the media favor MNOV or FBRX?

Do analysts rate MNOV or FBRX?

Do insiders and institutionals believe in MNOV or FBRX?

Which has preferable valuation and earnings, MNOV or FBRX?

Is MNOV or FBRX more profitable?

Summary

How does MediciNova compare to Niagen Bioscience?

Do institutionals and insiders believe in NAGE or MNOV?

Which has more volatility & risk, NAGE or MNOV?

Is NAGE or MNOV more profitable?

Does the media refer more to NAGE or MNOV?

Do analysts recommend NAGE or MNOV?

Which has preferable earnings & valuation, NAGE or MNOV?

Summary

How does MediciNova compare to Surrozen?

Do analysts rate MNOV or SRZN?

Which has more volatility and risk, MNOV or SRZN?

Is MNOV or SRZN more profitable?

Which has stronger earnings and valuation, MNOV or SRZN?

Do institutionals and insiders have more ownership in MNOV or SRZN?

Does the media favor MNOV or SRZN?

Summary

How does MediciNova compare to Siga Technologies?

Does the media prefer MNOV or SIGA?

Do insiders and institutionals hold more shares of MNOV or SIGA?

Which has preferable valuation and earnings, MNOV or SIGA?

Do analysts recommend MNOV or SIGA?

Is MNOV or SIGA more profitable?

Which has more risk & volatility, MNOV or SIGA?

Summary

How does MediciNova compare to Inhibikase Therapeutics?

Do institutionals and insiders believe in MNOV or IKT?

Does the media prefer MNOV or IKT?

Which has preferable valuation & earnings, MNOV or IKT?

Is MNOV or IKT more profitable?

Which has more risk & volatility, MNOV or IKT?

Do analysts prefer MNOV or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools